NDAINJECTIONINJECTABLE
Approved
Jul 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ACHROMYCIN (procaine hydrochloride; tetracycline hydrochloride) by Pfizer is clinical pharmacology novocain stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. First approved in 1954.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACHROMYCIN is a fixed combination of procaine hydrochloride (local anesthetic) and tetracycline hydrochloride (broad-spectrum antibiotic) administered by injection. Procaine stabilizes neuronal membranes to effect local anesthesia with rapid onset (2-5 minutes) and short duration (1-1.5 hours), while tetracycline provides antimicrobial coverage. This combination product addresses both pain management and infection control in a single formulation.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), team size is likely minimal and focused on maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY NOVOCAIN stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. NOVOCAIN lacks surface anesthetic activity. The onset of action is rapid (2 to 5 minutes) and the duration of action is relatively…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ACHROMYCIN offers minimal career dynamism; zero linked job openings and LOE-stage lifecycle indicate this is a legacy maintenance portfolio assignment with no growth trajectory. Working on this product provides stability but limited learning and advancement compared to growth-stage therapeutics.
Brand Manager
Worked on ACHROMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.